Why is it necessary to separate lipids when compounding pharmaceutical preparations?

Why lipids are separated during compounding

Because mixing lipids indiscriminately destabilizes formulations and increases patient risk (e.g., emulsion cracking, particle growth, peroxidation, and infusion reactions), you should separate or stage-add lipids to preserve emulsion stability and sterility, thereby protecting morbidity, mortality, and quality of life. 1, 2

• Frame with guideline intent

  • ESPEN: Use two-in-one (amino acids + dextrose) without lipids when lipid inclusion makes the formulation pharmaceutically unstable; add lipids separately or via three-chamber systems mixed immediately before infusion to minimize manipulation and instability risks 1.
  • Pediatric PN guidance: Lipid emulsions are inherently peroxidation-prone; light protection and controlled administration reduce oxidative injury and mortality in neonates, supporting handling lipids as distinct, protected components when needed 2.

• Practical reasons to separate lipids in compounding

  • Emulsion stability
    • Avoids “cracking” and phase separation when electrolytes, high dextrose, or pH shifts destabilize lipid droplets; two-in-one PN with separate lipid prevents incompatible admixtures 1.
  • Oxidation/photoperoxidation control
    • Lipid emulsions, especially PUFA-rich, require light protection; handling them separately allows validated light-protected tubing and practices linked to lower neonatal mortality and toxicity 2.
  • Sterility and manipulations
    • Three-chamber systems are mixed just before use to limit contamination; individually compounded AIO bags have limited stability and benefit from segregating lipids when stability is uncertain 1.
  • Dose flexibility and monitoring
    • Enables precise lipid dosing (e.g., fish-oil–containing ILEs, total daily lipid limits) and triglyceride monitoring without reformulating the whole PN bag 1.
  • Physical-chemical pitfalls
    • Prevents microphase separation and release variability seen in lipid systems during storage; staging lipids reduces storage-induced structural changes that can alter drug delivery 3.
  • Device/administration considerations
    • Separate infusion or Y-site addition helps maintain uniform droplet distribution during prolonged administration and minimizes sedimentation-related variability 1, 4.

• When to keep lipids separate (actionable algorithm)

  • If any of the following are present, do NOT make an all-in-one; use two-in-one plus separate ILE:
    • Known/anticipated emulsion instability with the prescribed electrolytes, trace elements, or pH/osmolality targets 1.
    • Need for stringent light protection (preterm/neonatal PN; high-PUFA emulsions) to reduce oxidative injury and mortality 2.
    • Prolonged storage before administration or uncertain beyond-use dating for AIO admixtures 1.
    • Requirement for frequent lipid dose changes or temporary lipid holds (elevated TGs, propofol co-infusion) 1.
  • Otherwise:
    • Use industry three-chamber AIO and mix seals immediately pre-infusion to reduce manipulation/infection risk; add vitamins/trace elements just before use per stability guidance 1.

• Common pitfalls to avoid

  • Adding high concentrations of divalent cations (e.g., Ca2+, Mg2+) to AIO with lipids—risk of emulsion destabilization; separate lipids if needed 1.
  • Failing to light-protect ILEs in neonates—associated with oxidative damage; always use light-protected tubing and continuous 24 h infusion when appropriate 2.
  • Long pre-infusion hang/storage times for mixed AIO—promotes phase changes; prefer just-in-time mixing or separate ILE 1.
  • Assuming stability across brands/concentrations—verify compatibility for each formulation; default to separation if uncertain 1.

• Strength and recency of evidence

  • Primary guidance: ESPEN PN definitions and practice around two-in-one vs all-in-one (strong consensus) 1.
  • Pediatric lipid handling and light protection with outcome signal (mortality reduction) supports separate, protected management of ILEs when risk is high 2.